Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

loodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... TOKYO , April 21, 2015  EBD ... has just announced Medtech Partnering Forum 2015 , ... industry. The event, held May 28–29 in ... medtech partnering conference in Japan . ... developments in the rapidly changing medical technology industry in ...
(Date:4/21/2015)... 21, 2015 Amgen (NASDAQ: AMGN ) ... 2015. Key results include: , Total revenues increased ... $5,033 million, with 12 percent product sales growth driven ... (denosumab), EPOGEN ® (epoetin alfa), Sensipar ® ... foreign exchange rates impacted total revenue and product sales ...
(Date:4/21/2015)... April 21, 2015  Inmark,s acquisition of Saf-T-Pak ... Dangerous Goods Training, specifically Division 6.2.  For over ... Goods training programs focusing on IATA, ICAO, US ... regulations. "We were particularly interested in ... their multilingual internet training programs," said David ...
Breaking Medicine Technology:Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 2Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2
... 21, 2012  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Phase 1 clinical program with their investigational product ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine ... issue of the New England Journal of ...
... 2012   Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: ... owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") are pleased ... the Diet, Vitamin & Sports Nutrition Expo to be ... Fort Lauderdale, Florida on July 15-17, 2012.  As part ...
Cached Medicine Technology:Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody 2Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody 3Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody 4Sunpeaks Ventures to Participate in ECRM Conference and Expo 2Sunpeaks Ventures to Participate in ECRM Conference and Expo 3
(Date:4/21/2015)... The International Journal of Chronic ... “ COPD and its association with smoking in the ... and women from ten diverse areas ”. , As ... smoke ~40% of the world’s cigarettes, but the substantial ... too recent for the full eventual health consequences to ...
(Date:4/21/2015)... April 21, 2015 My Patriot Supply ... offer the latest innovation in home water filtration: ... filtration system that makes existing gravity-fed filters obsolete. An ... federal and industry standards for water filtration. With an ... for a typical household. , The Alexapure Pro™ takes ...
(Date:4/21/2015)... On April 2, 2015, Elle Magazine, in ... Jenner Lips With Disastrous Results,” reported that ... attempting an at-home lip augmentation process. The ... an airlock around one’s mouth for several minutes will ... Kylie Jenner’s now famous pout. (see: goo.gl/dFQW2L) , “Truth ...
(Date:4/21/2015)... 2015 “ ZeroWire ” was featured ... which takes a look at the latest and coolest ... a special reporter for NewsWatch and a technology expert, ... is a security system and lifestyle management hub. , ... over 2 million burglaries in 2010. It goes without ...
(Date:4/21/2015)... Phoenix, AZ and Lewisville, TX (PRWEB) April 21, 2015 ... and Adeptus Health (NYSE:ADPT) announced today it is opening ... facility will be located in Chandler, Arizona and will ... is also part of the Dignity Health and Adeptus ... of Dignity Health Chandler Regional and Mercy Gilbert Medical ...
Breaking Medicine News(10 mins):Health News:COPD and smoking in the Mainland China published by Dove Medical Press 2Health News:COPD and smoking in the Mainland China published by Dove Medical Press 3Health News:Preparedness Leader My Patriot Supply Unveils the New Alexapure Pro™ Water Filter 2Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3
... PITTSBURGH , Jan. 28 Developing comprehensive ... will be the subject of the annual spring conference of ... is part of UPMC and based in Pittsburgh . ... Young Adults and Families," will put special emphasis on successful ...
... , Jan. 28 DNA Medicine Institute, ... innovation, today announced it has been awarded a Phase ... National Aeronautics and Space Administration (NASA).  The contract is ... health analysis in a single drop of blood.  The ...
... The nectar of the almond tree produces an extraordinary and ... this poison in its flowers, nectar. A study carried out ... mysteriously drawn to the toxic substance. Has the almond ... group of researchers at the Department of Environmental and Evolutionary ...
... ... Bowl advertising throughout the economic ups and downs of the decade. , ... Pennington, NJ (PRWEB) January 28, 2010 -- In ... the market research firm, Gallup & Robinson, Inc., overall attitudes towards Super Bowl advertising have ...
... not always a benefit, study of seniors suggests , THURSDAY, ... overweight will kill you, a new Australian study finds that ... to die over a 10-year period than their normal-weight peers. ... of the American Geriatrics Society , conflicts with research that ...
... , Crohn,s & Colitis Foundation of America ... Scored During the 2009 Season , NEW YORK , ... America (CCFA) today announced the culmination of the second consecutive year ... David Garrard , quarterback of the Jacksonville Jaguars ® (1) ...
Cached Medicine News:Health News:Community Care Hosts Conference on Behavioral Health Services for Children 2Health News:Community Care Hosts Conference on Behavioral Health Services for Children 3Health News:NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR 2Health News:The almond tree's secret weapon 2Health News:The almond tree's secret weapon 3Health News:Super Bowl Advertising, In Good Times And Bad 2Health News:Super Bowl Advertising, In Good Times And Bad 3Health News:Over 70 and Overweight May Add Years to Life 2Health News:Pro Quarterback David Garrard Raises $180,000 for Crohn's Disease Education and Research During 2009 Football Season 2Health News:Pro Quarterback David Garrard Raises $180,000 for Crohn's Disease Education and Research During 2009 Football Season 3Health News:Pro Quarterback David Garrard Raises $180,000 for Crohn's Disease Education and Research During 2009 Football Season 4
... Prep Pads are known ... including bacteria, fungi, viruses, ... Iodine is virtually non-irritating ... mucus membranes. It is ...
BETADINE Solution Swab Aid antiseptic pads are for quick and easy skin degerming. Individually wrapped pads, saturated with 10% povidone-iodine solution, offer the advantages of BETADINE Solution in ...
... offer convenience, low cost, ease of use. The ... package is terminally sterilized, ensuring the safest possible ... Pads prepare the skin for improved adhesion of ... a thin film on the skin's surface. This ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: